Wyeth 3004

Inactive Studies

A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer.